ViCardio®, (Website) a unique blood pressure monitor developed in the UK, has beaten global competition in the prestigious IDTechEx awards, held in Berlin.
The judges were impressed by Tarilian Laser Technologies' patented biosensor used in ViCardio, which is central in allowing ViCardio® to be the world’s first non-invasive, beat-to-beat, blood pressure monitor.
Winning the Best New Wearable Technology Device Award at IDTechEx comes on the back of parent company, Tarilian Laser Technologies (TLT), being just one of six firms chosen by PwC to represent the UK in the Great Festival of Innovation in Hong Kong last month.
TLT & ViCardio CEO Dr Sandeep Shah said:
“{{We are delighted to win the Best New Wearable Technology Award, especially coming so quickly after being part of the PwC delegation to Hong Kong}}. This reflects the potential of ViCardio® to transform the patient experience, as well as the strength of the UK technology sector.
The global wearables market is growing rapidly and we’re confident that ViCardio® will become a key player in the sector, creating valuable export opportunities and jobs along the way.”
IDTechEx have estimated that the global wearable technology will reach over 150bn USD annually by 2027, across a number of categories, including medical devices, fitness trackers and smartwatches. UK companies such as TLT are well-placed to take advantage of this growing market.
The judges at IDTechEx, Matthew Heasley, from GSK, and Dr Akira Sakaigawa, from Huawei commented that
“ViCardio's device has the potential to be revolutionary in blood pressure monitoring, so we are delighted to recognise this potential via this award”.
Dr David Pearce, accepting the award in Berlin, said:
“We’re very proud to have been honoured by the largest emerging technologies conference in Europe. UK wearables technology is becoming a global leader and we are playing a major part in that growth.”
Contact: press@vicardio.com
ViCardio Website
---------END------------
Notes to Editors
About IDTechEx
The IDTechEx Show! is hosted by IDTechEx. Since 1999 IDTechEx has provided independent market research, business intelligence and events on emerging technology to clients in over 80 countries.
From the IDTechEx judges:
Each year at the IDTechEx Show!, two companies are honoured for their achievements in developing and commercialising different aspects of wearable technology. This year the awards were judged by Mr Matthew Heasley (GSK) and Dr Akira Sakaigawa (Huawei) with support from the independent analyst team with IDTechEx Research.
As the ecosystem around various wearable products matures at different rates, significant developments at both the product and component level that are required to move the market towards the next generation. Both the high volume and wide diversity of applicants to the award reflected the ongoing spirit within this industry, and the judges commented as to the difficulties selecting just two winners from a list of impressive achievements.
The winner of the Best New Wearable Technology Device: ViCardio
Reasons for choice: Blood pressure remains one of the most challenging vital signs to characterise. ViCardio's non-invasive technique does not require the traditional inflating cuff, and also removes the need for individual calibration which has been a requirement in previous attempts at cuff-less, non-invasive monitoring. The device is currently being tested in clinical trials, with the aim of confirming the quality of the data. ViCardio's device has the potential to be revolutionary in blood pressure monitoring, so we are delighted to recognise this potential via this award.
Global, wearable technologies market
ID TechEX Review
Background to the development of ViCardio®
Tarilian Laser Technologies Ltd (TLT), a global Innovator in medical device, digital technology and engineering, announces the 2018 planned market launch of its remarkable and unique Cuffless continuous beat-to-beat blood pressure monitoring solution, ViCardio® (www.vicardio.com).
ViCardio® is based upon TLT’s State of The Art engineering platform delivering both a high performance and aesthetic Medical Wearable Device. The outstanding TLT device is based upon its proprietary and internationally patented opto-electronic sensor which instantly – within a second of application – delivers a continuous and highly accurate* blood pressure reading – similar to the output that is generated from an internal invasive arterial line. In contrast to all other technologies, TLT is easy and extremely comfortable to apply – with no cuff, no application pressure and no calibration required at all.
Unlike other attempts at cuffless technology over the past 50 years – which have relied on invasion of energy into the body and reflection back to a detector – which is problematic and highly inaccurate – {{ViCardio has broken a major barrier in sensor technology}} and developed a high-fidelity system that accurately* and effectively generates the most important surface physiological parameters that determine blood pressure. This technology which has over 37 patents is a paradigm shift and will create a whole new series of applications in consumer and hospital care.
The regular and accurate measurement of blood pressure is crucial for patients wishing to achieve the best understanding and control of this condition, that now touches the lives of over 50% of the adult population. Current cuff-based products are not well liked by patients as they cause discomfort and are cumbersome to carry. They also require frequent calibration to remain of any clinical value. Other emerging devices rely on light based invasive sensors (similar to the common heart rate wearable sensors) are highly inaccurate and are not serious contenders to gain FDA/CE Mark approval.
The TLT sensor will be available to clinicians and consumers and its ViCardio® brand are now set to disrupt the dynamic and evolving multi-billion dollar Medical Wearable and Luxury Technology markets. Following the conclusion of its final clinical trial (details below), it is anticipated that initial orders will be delivered to clinicians and consumers in Q4 2018.
People
Tarilian Laser Technologies is led by a family team, Dr Sandeep Shah and Nita Shah . They have combined their medical and electronic engineering backgrounds over several years to pursue the development of the ground-breaking TLT sensor.
Having achieved clinical trial results in 2012 within the CE/FDA approval tolerances, they have since focused on the further miniaturisation of the sensor and improvements in accuracy* so as to allow TLT to enter the sensor into a second clinical trial using the highest scrutiny possible, that of comparison to intra-arterial lines used in intensive care environments using the SP-10 protocol. This trial, currently in progress at The Barts Heart Centre, is anticipated to complete in Q2 of 2018 and its results will form the basis of their CE/FDA certifications.
Steve Schaefer , patent attorney and engineer by training, moved from his position as the Head of MedTech at the prestigious US patent firm Fish and Richardson in September 2017 to become the third executive director of TLT and the lead of its North American operation. Steve had led the team that had worked on securing the extensive patent portfolio since 2007.
Dr David Pearce , a leading Physician, Entrepreneur and expert in digital technology and communications, has recently joined the TLT Non-Executive Advisory Board.
